Strategic partnerships Acuitas is actively expanding collaborations with global pharma and biotech players (e.g., CREATE Medicines, Circio AB, Genflow Biosciences, RNA technologies partners) and with academic institutions, indicating strong sales potential through co-development and technology licensing of LNP delivery platforms.

Next-gen LNP opportunities The company is advancing next-generation LNPs for extrahepatic and in vivo CAR-T therapies, epigenetic medicines, multisite vaccines, and personalized cancer vaccines, presenting upsell and cross-sell avenues to integrate their delivery systems with clients pursuing innovative nucleic acid therapeutics.

Clinical validation A robust track record including two approved products and 33 clinical trials in three years demonstrates proven efficacy and reliability of Acuitas’ LNP technology, a strong marketing point when engaging with potential customers seeking proven delivery solutions.

Global market signaling Active participation in major conferences (ASGCT, mRNA Health Conference) and a growing list of international partnerships signal rising demand for LNP delivery expertise, suggesting timing is favorable for outreach to large and mid-size biotechs expanding into mRNA and gene therapies.

Revenue readiness Revenue range of 100M–250M with a scalable platform and a mid-size employee base positions Acuitas as a credible collaborator for mid-market to larger partners seeking to de-risk development timelines through validated LNP delivery capabilities.